Unicycive Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Unicycive Therapeutics, Inc. (UNCY) on June 21, 2024, covering events occurring on June 20 and June 21, 2024. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report is strictly administrative regarding corporate governance.
Material Changes
- Authorized Share Increase: On June 20, 2024, stockholders approved an amendment to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000 shares.
- Regulatory Filing: On June 21, 2024, the Company filed a Certificate of Amendment with the Delaware Secretary of State to formalize the increase in authorized shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document solely reports the procedural completion of the share authorization amendment.
Investor Verification Checklist
- Verify the full text of the Certificate of Amendment filed as Exhibit 3.1 for specific terms.
- Confirm the current number of issued and outstanding shares to assess the impact of the increased authorization on potential dilution.
- Review the Company's most recent 10-Q or 10-K for actual financial performance, as this 8-K contains no financial data.